Axsome Therapeutics (AXSM) said Wednesday the US Food and Drug Administration accepted its new drug application for AXS-12 to treat cataplexy, or muscle weakness, in narcolepsy.
A target review date of May 1, 2027, has been set, and the FDA indicated it currently does not expect to convene an advisory committee meeting to evaluate the submission, the company said.
Shares of the company were up nearly 1% in Wednesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments